glp-1 receptor agonist bcbs Understanding agonists and their impact on drug discovery Cardiovascular Protective Properties of GLP-1

Understand about the investigational Alluvi Retatrutide 40 mg injection a GLP-1 + GIP + Glucagon triple-agonist studied for obesity

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.

2026: Acceleration and Market Transformation The coming year promises rapid evolution across innovation, policy, and market access

Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]

New research suggests that switching to a maintenance dose of GLP-1 medication could help lock in weight loss.

Ozempic Face After GLP-1 Weight Loss: How Fat Transfer Restores Natural Facial Volume GLP-1 medications have transformed the way people lose weight but for some, fast fat loss can also lead to unexpected changes in the face